Background: The combination of dihydroartemisinin and piperaquine is interested because of its efficiency and safety in treating malaria. Objective: To evaluate the influences of the fixed combination anti-malarial drug dihydroartemisinin plus piperaquine in constitutions and some biochemical and haematological indices of rabbits. Subject and Method: The sub-chronic toxicity of the fixed combination anti-malarial drug of 40 mg dihydroartemisinin plus 320 mg piperaquine phosphate (DHA-PQP), with the materials produced by Institute of Chemistry, in rabbits was investigated. Rabbits were treated daily by oral route with DHA-PQP at the dose regimens of 64 and 100 mg/kg per day for 28 consecutive days. Result and Conclusion: DHA-PQP did not affect on rabbits' constitutions. Generally, all rabbits had normal ingestions, activities, and defecations. Rabbits' body weights increased regularly along the study period and significantly increased between day 28 and day 0 (P < 0.05). At the dose regimen of 64 mg/kg per day for 28 consecutive days, DHA-PQP did not change significantly rabbits' biochemical indices (including GOT, GPT, bilirubin, creatinine and protein) and haematological. These changes were insignificantly different between the treated and control groups at the same study points (P > 0.05). With the dose regimen of 100 mg/kg, the combination did not affect significantly (P>0.05) on some rabbits' biochemical and haematological indices. But hemoglobin, erythrocyte count and rate of monocytes increased significantly on day 14 comparing to that the control group (P < 0.05) and became in normal limits on day 29 (P > 0.05). Protein concentration also increased significantly on days 14 and 29 comparing to that of day 0 (P < 0.05).
Dihydroartemisinin plus piperaquine combination ; constitutions ; haematological

Background: Continuation of previous study of screening traditional medicinal plants with anti-diabetic effect, the hypoglycemic effect of glue extracted from Fructus Lycii which was named HPD was study. Objective: to investigate the hypoglycemic effect of HPD on diabetic mice caused by different doses of streptozocine. Subjects and methods: causing diabetes by streptozocine at difference doses was used to collect glucose intolerance mice, mild diabetic mice and severe diabetic mice. The effect of HPD p.o. at several doses was evaluated after 3 days of use. Results: By oral allocation with the dose of 500 and 1.000mg/kg body-weight for 3 days, HPD inhibited increasing blood glucose in streptozocine-induced glucose intolerance mice (intraperitoneal STZ 100 mg/kg). HPD 1000 mg/kg body weight had the potent hypoglycemic effect on streptozocine-induced diabetic mice, reverse the blood glucose self control ability of mild streptozicine-induced diabetic mice (STZ 120 mg/kg), meanwhile can not stop a hyperglycemic effect of high dose of STZ (STZ 180 mg/kg). Conclusion: HPD has the potent anti-hyperglycemic effect on streptozocine -induced diabetic rats. Anti-hyperglycemic of HPD is indirect under present of insulin\r\n', u'\r\n', u'\r\n', u'
Cornus ; Mice ; Inbred NOD ; Streptozocine ;

BACKGROUND/AIMS: To compare the performance of a modified Glasgow Blatchford score (mGBS) to the Glasgow Blatchford score (GBS) and the pre-endoscopic Rockall score (RS) in predicting clinical interventions in Vietnamese patients with acute nonvariceal upper gastrointestinal bleeding (AN-VUGIB). METHODS: A prospective multicenter cohort study was conducted in five tertiary hospitals from May 2013 to February 2014. The mGBS, GBS, and pre-endoscopic RS scores were prospectively calculated for all patients. The accuracy of mGBS was compared with that of GBS and pre-endoscopic RS using area under the receiver operating characteristic curve (AUC). Clinical interventions were defined as blood transfusions, endoscopic or radiological intervention, or surgery. RESULTS: There were 395 patients including 128 (32.4%) needing endoscopic treatment, 117 (29.6%) requiring blood transfusion and two (0.5%) needing surgery. In predicting the need for clinical intervention, the mGBS (AUC, 0.707) performed as well as the GBS (AUC, 0.708; p=0.87) and outperformed the pre-endoscopic RS (AUC, 0.594; p<0.001). However, none of these scores effectively excluded the need for endoscopic intervention at a threshold of 0. CONCLUSIONS: mGBS performed as well as GBS and better than pre-endoscopic RS for predicting clinical interventions in Vietnamese patients with ANVUGIB.
Asian Continental Ancestry Group* ; Blood Transfusion ; Cohort Studies* ; Gastrointestinal Hemorrhage ; Hemorrhage* ; Humans ; Prognosis ; Prospective Studies* ; ROC Curve ; Tertiary Care Centers

The COVID-19 pandemic has caused millions of deaths and hundreds of millions of confirmed infections worldwide. This pandemic has prompted researchers to produce medications or vaccines to reduce or stop the progression and spread of this disease. A variety of previously licensed and marketed medications are being tested for the treatment and recurrence of SARS-CoV2, including favipiravir (Avigan). Favipiravir was recognized as an influenza antiviral drug in Japan in 2014, and has been known to have a potential in vitro activity against SARS-CoV-2, in addition to its broad therapeutic safety scope. Favipiravir was recently approved and officially used in many countries worldwide. Our review provides insights and up-to-date knowledge of the current role of favipiravir in the treatment of COVID-19 infection, focusing on preclinical and ongoing clinical trials, evidence of its efficacy against SARS-CoV-2 in COVID-19, side effects, anti-viral mechanism, and the pharmacokinetic properties of the drug in the treatment of COVID-19. Due to its teratogenic effects, favipiravir cannot be offered to expectant or pregnant mothers. The practical efficacy of such an intervention regimen will depend on its dose, treatment duration, and cost as well as difficulties in application.

Objectives: The prevalence of posttraumatic stress disorder (PTSD) has increased, particularly among individuals who have recovered from coronavirus disease 2019 (COVID-19) infection. Health literacy is considered a “social vaccine” that helps people respond effectively to the pandemic. We aimed to investigate the association between long COVID-19 and PTSD, and to examine the modifying role of health literacy in this association. Methods: A cross-sectional study was conducted at 18 hospitals and health centers in Vietnamfrom December 2021 to October 2022. We recruited 4,463 individuals who had recovered from COVID-19 infection for at least 4 weeks. Participants provided information about their sociodemographics, clinical parameters, health-related behaviors, health literacy (usingthe 12-item short-form health literacy scale), long COVID-19 symptoms and PTSD (Impact Event Scale-Revised score of 33 or higher). Logistic regression models were used to examine associations and interactions. Results: Out of the study sample, 55.9% had long COVID-19 symptoms, and 49.6% had PTSD.Individuals with long COVID-19 symptoms had a higher likelihood of PTSD (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.63–2.12; p < 0.001). Higher health literacy was associated with a lower likelihood of PTSD (OR, 0.98; 95% CI, 0.97–0.99; p = 0.001). Compared to those without long COVID-19 symptoms and the lowest health literacy score, those with long COVID-19 symptoms and a 1-point health literacy increment had a 3% lower likelihood of PTSD (OR, 0.97; 95% CI, 0.96–0.99; p = 0.001). Conclusion Health literacy was found to be a protective factor against PTSD and modified the negative impact of long COVID-19 symptoms on PTSD.